Citations

Mayo Clinic

Showing 10 of 108572 citations.

Drosophila ClC-c Is a Homolog of Human CLC-5 and a New Model for Dent Disease Type 1
Reynolds, Carmen J. , Gillen, Christopher M. , Burke, Richard , Tsering, Yula , Loucks, Emi, Judd-Mole, Sebastian , Dow, Julian A. T. , Romero, Michael F. , Dow, Julian A T , Romero, Michael F

Kidney360 | January 18, 2024 | Volume: 5 | Issue: 3 | Pages: 414-426

10.34067/kid.0000000000000352 | PMID 38233994 Get It

Key Points Drosophila can be a model for Dent Disease type 1. Drosophila Clc-C mutations function similar to human CLC-5 Dent 1 mutations. Background Drosophila serve as exceptional alternative models for in vivo and ex vivo research and may provide an avenue for in-depth investigation for human ClC-5 and Dent disease type 1 (DD1). The Drosophila ClC-c (CG5284) has sequence homology with human ClC-5 and is hypothesized to encompass similar functional and phenotypical roles with ClC-5 and variants that cause DD1. Methods Ion transport function and activity of Drosophila ClC-c and homologous DD1 variants were assessed by voltage clamp electrophysiology. Membrane localization was demonstrated in Drosophila expressing a GFP-labeled construct of ClC-c. Genetic expression of an RNAi against ClC-c mRNA was used to generate a knockdown fly that serves as a DD1 disease model. Tubule secretion of cations and protein were assessed, as well as the crystal formation in the Malpighian tubules. Results Voltage clamp experiments demonstrate that ClC-c is voltage-gated with Cl − -dependent and pH-sensitive currents. Inclusion of homologous DD1 mutations pathogenic variants (S393L, R494W, and Q777X) impairs ClC-c ion transport activity. In vivo expression of ClC-c-eGFP in Malpighian tubules reveals that the membrane transporter localizes to the apical membrane and nearby cytosolic regions. RNAi knockdown of ClC-c (48% decreased mRNA expression) causes increased secretion of both urinary protein and Ca 2+ and increased occurrence of spontaneous tubule crystals. Conclusions Drosophila ClC-c shows orthologous function and localization to human ClC-5. Thus, Drosophila and ClC-c regulation may be useful for future investigations of Cl − transport, Ca 2+ homeostasis, and urinary protein loss in DD1.
Initial Antihypertensive Prescribing in Relation to Blood Pressure Among Florida Medicaid and Medicare Recipients in the OneFlorida+ Research Consortium
Smith, Kayla , Keshwani, Shailina , Walsh, Marta , Winterstein, Almut G. , Gurka, Matthew J. , Libby, Anne M. , Hogan, William R. , Pepine, Carl J. , Cooper‐DeHoff, Rhonda M. , Smith, Steven M. , Smith, Kayla M , Walsh, Marta G, Libby, Anne , Hogan, William , Smith, Steven M , Cooper‐DeHoff, Rhonda M.

Hypertension | January 17, 2024 | Volume: 81 | Issue: 2 | Pages: No page available

10.1161/hypertensionaha.123.21901 | PMID 38232142 Get It

Patient characteristics associated with acute kidney injury following coronary angiography
Knott, Jonathan D , Engheta, Michael , Michel, Jeffery, Mixon, Timothy A. , Widmer, R. Jay , Knott, Jonathan , Widmer, Robert Jay

Baylor University Medical Center Proceedings | January 17, 2024 | Volume: 37 | Issue: 3 | Pages: 382-387

10.1080/08998280.2024.2301903 | PMID 38628321 Get It

2dGBH: Two-dimensional group Benjamini–Hochberg procedure for false discovery rate control in two-way multiple testing of genomic data
Yang, Lu , Chen, Jun , Chen, Jun , Wang, Pei

Bioinformatics | January 17, 2024 | Volume: 40 | Issue: 2 | Pages: No page available

10.1093/bioinformatics/btae035 | PMID 38244568 Get It

Abstract Motivation Emerging omics technologies have introduced a two-way grouping structure in multiple testing, as seen in single-cell omics data, where the features can be grouped by either genes or cell types. Traditional multiple testing methods have limited ability to exploit such two-way grouping structure, leading to potential power loss. Results We propose a new 2D Group Benjamini–Hochberg (2dGBH) procedure to harness the two-way grouping structure in omics data, extending the traditional one-way adaptive GBH procedure. Using both simulated and real datasets, we show that 2dGBH effectively controls the false discovery rate across biologically relevant settings, and it is more powerful than the BH or q-value procedure and more robust than the one-way adaptive GBH procedure. Availability and implementation 2dGBH is available as an R package at: https://github.com/chloelulu/tdGBH. The analysis code and data are available at: https://github.com/chloelulu/tdGBH-paper.
Development and validation of algorithms for identifying lines of therapy in multiple myeloma using real-world data
Romanus, Dorothy , Fraeman, Kathy , Saragoussi, Delphine , Buus, Rebecca Morris, Nguyen, Binh Thanh , Cherepanov, Dasha , Lamerato, Lois , Berger, Ariel , Lamerato, Lois , Berger, Ariel , Ailawadhi, Sikander , Shah, Surbhi

Future Oncology | January 17, 2024 | Volume: 20 | Issue: 15 | Pages: 981-995

10.2217/fon-2023-0696 | PMID 38231002 Get It

TMEM106B core deposition associates with TDP-43 pathology and is increased in risk SNP carriers for frontotemporal dementia
Marks, Jordan D. , Ayuso, Virginia Estades, Carlomagno, Yari , Yue, Mei, Todd, Tiffany W. , Hao, Ying , Li, Ziyi , McEachin, Zachary T. , Shantaraman, Anantharaman , Daughrity, Lillian M. , Jansen‐West, Karen , Calliari, Anna , Bejarano, Jesús González , DeTure, Michael , Rawlinson, Bailey, Castanedes‐Casey, Monica , Lilley, Meredith T. , Donahue, Megan , Jawahar, Vidhya Maheswari, Petersen, Ronald C. , Oskarsson, Björn , Graff‐Radford, Neill R. , Josephs, Keith A. , Seyfried, Nicholas T., Ward, Michael E. , Zhang, Yong‐Jie , Prudencio, Mercedes , Petrucelli, Leonard , Cook, Casey , Duong, Duc M , Daughrity, Lillian M , Jansen-West, Karen R , Shao, Wei , Calliari, Anna , Bejarano, Jesus Gonzalez , DeTure, Michael , Castanedes-Casey, Monica , Lilley, Meredith T , Donahue, Megan H , Boeve, Brad , Petersen, Ronald C , Knopman, David S. , Oskarsson, Björn , Wszolek, Z.K. , Dickson, Dennis W , Josephs, Keith A , Qi, Yue A , Seyfried, Nicholas T , Ward, Michael E , Zhang, Yong-Jie , Prudencio, Mercedes , Petrucelli, Leonard , Cook, Casey N , Li, Ziyi , Shantaraman, Anantharaman , Estades Ayuso, Virginia , Shao, Wei , Bharathi, Vidhya , Boeve, Bradley F. , Knopman, David S. , Wszołek, Zbigniew K. , Dickson, Dennis W. , Qi, Yue , Seyfried, Nicholas T.

Science Translational Medicine | January 17, 2024 | Volume: 16 | Issue: 730 | Pages: No page available

10.1126/scitranslmed.adf9735 | PMID 38232138 Get It

Genetic variation at the transmembrane protein 106B gene ( TMEM106B) has been linked to risk of frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) through an unknown mechanism. We found that presence of the TMEM106B rs3173615 protective genotype was associated with longer survival after symptom onset in a postmortem FTLD-TDP cohort, suggesting a slower disease course. The seminal discovery that filaments derived from TMEM106B is a common feature in aging and, across a range of neurodegenerative disorders, suggests that genetic variants in TMEM106B could modulate disease risk and progression through modulating TMEM106B aggregation. To explore this possibility and assess the pathological relevance of TMEM106B accumulation, we generated a new antibody targeting the TMEM106B filament core sequence. Analysis of postmortem samples revealed that the TMEM106B rs3173615 risk allele was associated with higher TMEM106B core accumulation in patients with FTLD-TDP. In contrast, minimal TMEM106B core deposition was detected in carriers of the protective allele. Although the abundance of monomeric full-length TMEM106B was unchanged, carriers of the protective genotype exhibited an increase in dimeric full-length TMEM106B. Increased TMEM106B core deposition was also associated with enhanced TDP-43 dysfunction, and interactome data suggested a role for TMEM106B core filaments in impaired RNA transport, local translation, and endolysosomal function in FTLD-TDP. Overall, these findings suggest that prevention of TMEM106B core accumulation is central to the mechanism by which the TMEM106B protective haplotype reduces disease risk and slows progression.
What Is the Relevance of Post-Reduction MRI Today and Where Do We Go from Here?
Grigoriou, Emmanouil , Shaughnessy, William J.

Journal of Bone and Joint Surgery | January 17, 2024 | Volume: 106 | Issue: 2 | Pages: e3

10.2106/jbjs.23.01233 | PMID 38231196 Get It

Current Status and Treatment of Rapid Cycling Bipolar Disorder
Miola, Alessandro , Frye, Mark A. , Tondo, Leonardo , Baldessarini, Ross J.

Journal of Clinical Psychopharmacology | January 17, 2024 | Volume: 44 | Issue: 2 | Pages: 86-88

10.1097/jcp.0000000000001807 | PMID 38230858 Get It

Abstract Background Rapid cycling (RC) at least 4 recurrent episodes per year in bipolar disorder (BD) has been recognized since the 1970s. We now comment on our recent review of the topic and extensive RC analysis in a large clinical cohort, emphasizing therapeutics research. Comments Prevalence of RC-BD averages 36% for any year versus 22% in the preceding year. Rapid cycling is not a consistent feature over many years, although average long-term, annual recurrence rates are greater in RC-BD patients. Risk of RC may be somewhat greater among women and with older ages. It is also associated with cyclothymic temperament, prominent depression, and mood-switching with antidepressant treatment and is associated with increased suicidal risk. Treatment of individual episodes in RC-BD and effective long-term prevention remain inadequately studied, although antidepressant treatment can worsen RC. Some research supports treatment with aripiprazole, lamotrigine, and lithium, and interest in second-generation antipsychotics is emerging. All such options are used in various inadequately evaluated combinations. Conclusions Rapid cycling is prevalent among BD patients but seems to vary in risk over time without evidence of progressive worsening. Treatment of acute episodes in RC-BD patients and effective long-term preventive management require much more intensive investigation.
Patient-targeted education (ePRO-E) to increase ePRO intent within an Alliance clinical trial (A221805-SI1)
Smith, Elizabeth , Hillman, Shauna L., Scott, Mary R , Harlos, Elizabeth, Wills, Rachel, Loprinzi, Charles L. , Zahrieh, David M. , Lavoie Smith, Ellen M , Hillman, Shauna, Cho, Youmin , Wilson, Christina M.

JNCI Cancer Spectrum | January 17, 2024 | Volume: 8 | Issue: 1 | Pages: No page available

10.1093/jncics/pkae002 | PMID 38230706 Get It

Abstract Background The Patient Cloud ePRO app was adopted by the National Cancer Institute National Clinical Trials Network (NCTN) to facilitate capturing electronic patient-reported (ePRO) outcome data, but use has been low. The study objectives were to test whether a patient-targeted ePRO educational resource (ePRO-E) would increase ePRO intent (number of users) and improve data quality (high quality: ≥80% of the required surveys submitted) within an ongoing NCTN study. Methods The ePRO-E intervention, a patient-targeted educational resource (written material and 6-minute animated YouTube video), was designed to address ePRO barriers. ePRO intent and data quality were compared between 2 groups (N = 69): a historical control group and a prospectively recruited intervention group exposed to ePRO-E. Covariates included technology attitudes, age, sex, education, socioeconomic status, and comorbidity. Results Intervention group ePRO intent (78.8%) was statistically significantly higher than historical control group intent (47.1%) (P = .03). Patients choosing ePRO versus paper surveys had more positive and higher technology attitudes scores (P = .03). The odds of choosing ePRO were 4.7 times higher (95% Confidence Interval [CI] = 1.2 to 17.8) (P = .02) among intervention group patients and 5.2 times higher (95% CI = 1.3 to 21.6) (P = .02) among patients with high technology attitudes scores, after controlling for covariates. However, the 80% submission rate (percentage submitting ≥80% of required surveys) in the ePRO group (30.6%) was statistically significantly lower than in the paper group (57.9%) (P = .05). Conclusions ePRO-E exposure increased ePRO intent. High technology attitudes scores were associated with ePRO selection. Since the ePRO survey submission rate was low, additional strategies are needed to promote high-quality data submission.
Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study
Ahn, Daniel H. , Barzi, Afsaneh , Ridinger, Maya , Samuëlsz, Errin , Subramanian, Ramanand A. , Wu, Chu-Chiao, Croucher, Peter J.P. , Smeal, Tod , Kabbinavar, Fairooz F. , Lenz, Heinz‐Josef , Wu, Chu-Chiao

Clinical Cancer Research | January 17, 2024 | Volume: 30 | Issue: 10 | Pages: 2039-2047

10.1158/1078-0432.ccr-23-3053 | PMID 38231047 Get It

Abstract Purpose: Onvansertib is a highly specific inhibitor of polo-like kinase 1 (PLK1), with demonstrated safety in solid tumors. We evaluated, preclinically and clinically, the potential of onvansertib in combination with chemotherapy as a therapeutic option for KRAS-mutant colorectal cancer. Patients and Methods: Preclinical activity of onvansertib was assessed (i) in vitro in KRAS wild-type and -mutant isogenic colorectal cancer cells and (ii) in vivo, in combination with irinotecan, in a KRAS-mutant xenograft model. Clinically, a phase Ib trial was conducted to investigate onvansertib at doses 12, 15, and 18 mg/m2 (days 1–5 and 14–19 of a 28-day cycle) in combination with FOLFIRI/bevacizumab (days 1 and 15) in patients with KRAS-mutant metastatic colorectal cancer who had prior oxaliplatin exposure. Safety, efficacy, and changes in circulating tumor DNA (ctDNA) were assessed. Results: In preclinical models, onvansertib displayed superior activity in KRAS-mutant than wild-type isogenic colorectal cancer cells and demonstrated potent antitumor activity in combination with irinotecan in vivo. Eighteen patients enrolled in the phase Ib study. Onvansertib recommended phase II dose was established at 15 mg/m2. Grade 3 and 4 adverse events (AE) represented 15% of all treatment-related AEs, with neutropenia being the most common. Partial responses were observed in 44% of patients, with a median duration of response of 9.5 months. Early ctDNA dynamics were predictive of treatment efficacy. Conclusions: Onvansertib combined with FOLIFRI/bevacizumab exhibited manageable safety and promising efficacy in second-line treatment of patients with KRAS-mutant metastatic colorectal cancer. Further exploration of this combination therapy is ongoing. See related commentary by Stebbing and Bullock, p. 2005